{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:05:35Z","timestamp":1790201135660,"version":"4.1.0"},"reference-count":80,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"Gilead, CFF and the National Institute of Health","award":["5R01HL116226\u201302"],"award-info":[{"award-number":["5R01HL116226\u201302"]}]},{"name":"Cystic Fibrosis Foundation Research Development Program","award":["R457-CR11"],"award-info":[{"award-number":["R457-CR11"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.2217\/fmb.15.117","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T12:23:36Z","timestamp":1447763016000},"page":"1901-1912","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":52,"title":["Management of\n            <i>Pseudomonas Aeruginosa<\/i>\n            Infection in Cystic Fibrosis Patients using Inhaled Antibiotics with a Focus on Nebulized Liposomal Amikacin"],"prefix":"10.1080","volume":"10","author":[{"given":"Zarmina","family":"Ehsan","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center &amp; the University of Cincinnati, MLC 2021 3333 Burnet Avenue, Cincinnati, OH45220, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Clancy","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center &amp; the University of Cincinnati, MLC 2021 3333 Burnet Avenue, Cincinnati, OH45220, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,11,17]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282403"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043184"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2077"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.184"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950060207"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201404-166OC"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090314"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.004"},{"key":"e_1_3_3_11_1","unstructured":"Cystic Fibrosis Foundation Patient Registry Annual Data Report. 2015 (9 June 2015) ( 2013 )."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.08.004"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120577109"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5469.1251"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.2006\/005082-0"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2012.00983.x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/416740a"},{"key":"e_1_3_3_18_1","first-page":"91","article-title":"Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung","volume":"358","author":"Hogardt M","year":"2013","unstructured":"Hogardt M , HeesemannJ . Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung . Curr. Topics Microbiol. Immunol.358 , 91 \u2013 118 ( 2013 ).","journal-title":"Curr. Topics Microbiol. Immunol."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens3030680"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(11)60011-8"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(02)00141-8"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10100"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21442"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22658"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20023"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(11)60012-X"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.790366"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21117"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.3_suppl.118S"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.10.009"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-32"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2011.136"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20222"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2005.05.018"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200832"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479972309104661"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00018414"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.121657"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.04.003"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/am.22.6.1147-1151.1971"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.4.1.35"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2010.10.003"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22989"},{"key":"e_1_3_3_46_1","unstructured":"Chiesi Farmaceutici s.PA. Product portfolio. 2015. ( 2014 ). http:\/\/www.chiesi.uk.com\/product_portfolio\/ ."},{"key":"e_1_3_3_47_1","unstructured":"Chiesi USA Inc. . Bethkis? (tobramycin inhalation solution): Concentrated formulation for efficient nebulization. 2015 (Web page accessed April 6 2015) (2015) . 6 April 2015 ."},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.219"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950070413"},{"key":"e_1_3_3_50_1","first-page":"CD001021","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","volume":"3","author":"Ryan G","year":"2011","unstructured":"Ryan G , SinghM , DwanK . Inhaled antibiotics for long-term therapy in cystic fibrosis . Cochrane Database Syst. Rev.3 , CD001021 ( 2011 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.04.006"},{"key":"e_1_3_3_52_1","unstructured":"(Chmp) CFMPFHU . European Medicine Agency Assessment report: Vantobra ( 2015 )."},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1804OC"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21301"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.07.006"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03734.x"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328332e672"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202059"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.03.010"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0924OC"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1974.tb43277.x"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.791"},{"key":"e_1_3_3_64_1","unstructured":"Forest Pharmaceuticals I. Forest laboratories: Product website. 2015 (Date accessed October 26 2015) (2014) . ( 2014 )."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01744-10"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201008-1293OC"},{"key":"e_1_3_3_67_1","unstructured":"Aptalis Pharma I . Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsAptalis Pharma Inc. Announces Results of Phase 3 Studies of Aeroquin\u2122 (Levofloxacin Solution for Inhalation) Among Patients With Cystic Fibrosis and Chronic Lung Infection . NCT01270347 Study Mpex 209 and 207 ( 2013 )."},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22813"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00872-08"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn059"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2008.0693"},{"key":"e_1_3_3_72_1","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"11","author":"Langton Hewer SC","year":"2014","unstructured":"Langton Hewer SC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis . Cochrane Database Syst. Rev.11 , CD004197 ( 2014 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2008.0686"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0141-0"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.09.002"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16d30.x"},{"key":"e_1_3_3_77_1","first-page":"CD010004","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","volume":"12","author":"Waters V","year":"2012","unstructured":"Waters V , RatjenF . Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis . Cochrane Database Syst. Rev.12 , CD010004 ( 2012 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202230"},{"key":"e_1_3_3_79_1","volume-title":"2013 North American Cystic Fibrosis Conference (NACFC)","author":"Bilton D","year":"2013","unstructured":"Bilton D , PresslerT , FajacIet al. Phase 3 efficacy and safety data from randomized, multicenterstudy of liposomal amikacin for inhalation (Arikace\u00ae) compared with Tobi\u00ae incystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa . Presented at : 2013 North American Cystic Fibrosis Conference (NACFC) ( 2013 )."},{"key":"e_1_3_3_80_1","volume-title":"2014 North American Cystic Fibrosis Conference","author":"Bilton D","year":"2014","unstructured":"Bilton D , PresslerT , FajacIet al. Analysis of long-term liposomal amikacin for inhalation in patients with cysticfibrosis and chronic infection from Pseudomonas aeruginosa . Poster presented at : 2014 North American Cystic Fibrosis Conference . Atlanta, GA, USA , 9\u201311 October 2014 ."},{"key":"e_1_3_3_81_1","unstructured":"Acquire Media online news brief . Arikace meets primary endpoint of non-inferiority to Tobi in Phase 3 clinical trial in Europe and Canada to treat Pseudomonas aeruginosa in cystic fibrosis patients (2013) . 6 July 2015 ( 2013 )."},{"key":"e_1_3_3_82_1","unstructured":"US Food and Drug Administration . Products Designating an orphan product: Drugs and biological products ( 2015 ). http:\/\/www.fda.gov\/ForIndustry\/DevelopingProductsforRareDiseasesConditions\/HowtoapplyforOrphanProductDesignation ."}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.15.117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:50Z","timestamp":1719124730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.15.117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,17]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.2217\/fmb.15.117"],"URL":"https:\/\/doi.org\/10.2217\/fmb.15.117","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}